SOHO 2023 - 11th Annual Meeting of the Society of Hematologic Oncology
Sep 06 - Sep 09, 2023 | HoustonTXUS
LARVOL is not affiliated with 11th Annual Meeting of the Society of Hematologic Oncology and all trademarks, logos, and brand names are property of their respective owners
Showing 191 abstracts linked to Trials
Lisocabtagene Maraleucel (liso‑cel) in R/R Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Analysis of the Phase 1/2, Single‑Arm, Multicenter TRANSCEND CLL 004 Study
First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome‑Positive Acute Lymphocytic Leukemia
Improvement of Patient‑Reported Fatigue in IMerge Phase 3 Trial of Imetelstat vs Placebo in Heavily Transfused Non‑Del(5q) Lower‑Risk Myelodysplastic Syndromes Relapsed/Refractory/Ineligible for Erythropoiesis‑Stimulating Agents
Impact of Transfusion Burden on Health‑Related Quality of Life and Functioning in Patients With Myelofibrosis: Post Hoc Analysis of SIMPLIFY‑1 and ‑2
TRANSCEND FL: Phase II Study Results of Lisocabtagene Maraleucel (Liso‑Cel) in Patients With R/R Follicular Lymphoma (FL)
Luspatercept Versus Epoetin Alfa (EA) for Treatment of Anemia in Patients With Erythropoiesis‑Stimulating Agent (ESA)‑Naive Lower‑Risk Myelodysplastic Syndromes (LR‑MDS) Requiring Red Blood Cell (RBC) Transfusions: Data from the Phase III COMMANDS Study
Lisocabtagene Maraleucel (liso‑cel) in R/R Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Analysis of the Phase 1/2, Single‑Arm, Multicenter TRANSCEND CLL 004 Study
Epcoritamab + R2 Regimen and Responses in Patients With High‑Risk Follicular Lymphoma, Regardless of POD24 Status
Isatuximab (Isa) in Relapsed Multiple Myeloma (MM) Patients (pts) With Ultra‑High‑Risk (UHR) Cytogenetics: ICARIA‑MM and IKEMA Subgroup Analysis
Luspatercept Versus Epoetin Alfa (EA) for Treatment of Anemia in Patients With Erythropoiesis‑Stimulating Agent (ESA)‑Naive Lower‑Risk Myelodysplastic Syndromes (LR‑MDS) Requiring Red Blood Cell (RBC) Transfusions: Data from the Phase III COMMANDS Study
ELARA Trial Update: Long‑Term Clinical Outcomes and Correlative Efficacy Analyses of Tisagenlecleucel in Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL)
Lisocabtagene Maraleucel (Liso‑Cel) in R/R MCL: Primary Analysis Results From the MCL Cohort of the Single‑Arm, Multicenter, Phase I Seamless Design TRANSCEND NHL 001 Study
Pomalidomide, Daratumumab, and Dexamethasone After Lenalidomide Treatment in Patients With Relapsed or Refractory Multiple Myeloma (RRMM): Final Overall Survival (OS) Analysis of the Phase II MM‑014 Study
A Phase III, Open‑Label, Randomized Study to Evaluate the Efficacy and Safety of Single‑Agent Belantamab Mafodotin (Belamaf) Compared With Pomalidomide Plus Low‑Dose Dexamethasone (Pd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) (DREAMM‑3)
Longer Follow‑Up Reaffirms Subcutaneous Epcoritamab Induces Deep and Durable Complete Remissions in Patients With Relapsed/ Refractory Large B‑Cell Lymphoma: Updated Results From the Pivotal EPCORE NHL‑1 Trial